

Here is the retrosynthetic analysis for the shortcut synthesis of Tamiflu. This synthesis initiated by oxa-Michael addition of alcohol to acrolin, which was reported by Zhang et al,




Maybe a complete understanding of life and its evolution will never be possible. However, this will not certainly stop scientists from seeking the secret of the origin of life. Whitesides recently expressed the current state of understanding of the origin of life in frank words,
"Most chemists believe, as do I, that life emerged spontaneously from mixtures of molecules in the prebiotic Earth. How? I have no idea. Perhaps it was by the spontaneous emergence of “simple” autocatalytic cycles and then by their combination. On the basis of all the chemistry that I know, it seems to me astonishingly improbable."
.
Kelley et al. proposed a hypothesis for an inefficient GABA signaling system that resulted in unchecked pro-inflammatory cytokine production via the p38 MAP kinase pathway. p38 is a kinase target that regulates the production of inflammatory cytokines TNF, IL-1, IL-6, and PGE2. TNF, IL-1, and IL-6 are well-validated cytokines for controlling inflammation in rheumatoid arthritis (RA), and PGE2 is an essential mediator for inflammatory pain. However, most of the p38 projects failed to deliver drugs due to CNS toxicity. Are these CNS side effects linked to GABA?
The research team led by Ulrich Zeilhofer used genetically altered mice in experiments to target the GABA receptors that control spinal pain relay. They showed that the non-sedative benzodiazepine ligand L- 838417 (a GABA receptor ligand) is highly effective against inflammatory and neuropathic pain. Clomethiazole edisilate is a drug that acts on GABA receptor, which inhibits the p38 MAPK too. This small molecule does not have other p38 inhibitors' structural features, which seems to support this hypothesis. The task is to find which subtype of GABA responsible for the chronic pain. However, no direct link has been reported between GABA and p38 MAPK. The role of GABA in RA and pain development will encourage further integration of Immunology in clinical neuroscience. These findings may provide a rational basis for developing subtype-selective GABAergic drugs to treat RA and chronic pain.
Pharmaceutical companies are trying to fill their drug portfolio by optimizing the marketed drugs. Most recently launched drugs are structurally similar to already known drugs, with only minor differences. The most common drug optimization methods are:
1. Reactive metabolites:
An excellent example of this is venlafaxine (Effexor) and desvenlafaxine ( Pristiq). Desvenlafaxine is the metabolite of venlafaxine. The difference is that desvenlafaxine having O-H instead of O-Me.
2. Deuterated Drugs:
Switching a hydrogen atom with a heavier isotope such as deuterium, pharma companies hope that the deuterated drug survives longer in the body and fewer side effects because it can make a stronger chemical bond than hydrogen.
3. Racemic switching:
Racemic switching is the redevelopment in a single enantiomer from a first approved drug as a racemate; a better example is the Nexium. It is a predecessor Prilosec, a mixture of both S and R isomers. When Prilosec’s patent expired in 2001, the drugmaker was ready with Nexium, which contains only the S-isomer.
The proliferation of "me-too" drugs leads to beneficial cost reductions. However, in the end, the real question is about pharmaceutical innovation. While “me too” fills the development pipeline, the creativity is fading away in the art of drug discovery?
